{
  "id": 9845848,
  "title": "Kodiak Sciences to report phase 3 trial results Monday",
  "url": "https://urgent.news/2026/09/25/kodiak-sciences-to-report-phase-3-trial-results-monday",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-25T22:08:26.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/kodiak-sciences-to-report-phase-3-trial-results-monday-93CH-4918245"
  },
  "original_language": "en",
  "account": "Palo Alto, California - Kodiak Sciences Inc. (NASDAQ: KOD) is scheduled to reveal the key findings from its Phase 3 DAYBREAK study on Monday, September 28, as per a press release. The investigation assesses the efficacy of Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in addressing wet age-related macular degeneration. The biotech firm intends to conduct a webcast at 8:30 AM Eastern Time to present the results. Kodiak Sciences identifies itself as a precommercial retina-focused biotechnology enterprise. The company is currently engaged in three late-stage clinical endeavors, encompassing its entire portfolio. A webcast of this announcement will be accessible via the Events and Presentations segment on Kodiak’s investor relations website. Following the live presentation, an archived recording will remain available for a brief period.",
  "summary": null,
  "key_points": [
    "Kodiak Sciences to present Phase 3 trial results on September 28",
    "Study evaluates Zenkuda and KSI-501 for wet AMD treatment",
    "Webcast at 8:30 AM Eastern Time with archived recording available"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}